Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_3

33%

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 3Large-scale testing

2(33.3%)

N/ANon-phased studies

4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Detailed Status

Completed4

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 32 (33.3%)

N/A4 (66.7%)

Trials by Status

withdrawn117%

completed467%

terminated117%

Recent Activity

0 active trials

Showing 5 of 6

completednot_applicable

Clinical Trials (6)

Showing 6 of 6 trials

NCT03072628Not Applicable

E-cigarettes, Nicotine Inhaler, and Blood Vessel Function

Completed

NCT00482690Not Applicable

Analysis of Aldehyde Biomarkers of Exposure and Host Response

Terminated

NCT00468234Not Applicable

Validation of Biomarkers of Exposure and Host Response

Completed

NCT02004171Not Applicable

Electronic Cigarettes or Nicotine Inhaler for Smoking Cessation

Withdrawn

NCT01303861Phase 3

Concurrent Bupropion / Varenicline for Smoking Cessation

Completed

NCT00840242Phase 3

Smoking Reduction or Cessation With Nicotine Replacement Therapy

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6